The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression

RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (S...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore)
Main Authors: Roberto, Michela, Falcone, Rosa, Mazzuca, Federica, Archibugi, Livia, Castaldi, Nadia, Botticelli, Andrea, Osti, Mattia Falchetto, Marchetti, Paolo
Format: Artigo
Language:Inglês
Published: Wolters Kluwer Health 2017
Subjects:
5700
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728821/
https://ncbi.nlm.nih.gov/pubmed/29310420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000009023
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items